cancer-immunotherapy

Documents about cancer-immunotherapy

• The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy#152392ClinicalTrials.gov
• Study on the Efficacy and Safety of Transarterial Chemoembolization Combined With Targeted Immunotherapy in Patients With Unresectable Hepatocellular Carcinoma#162471ClinicalTrials.gov
• Selected De-escalation Radiotherapy for Postoperative Head and Neck Squamous Cell Carcinoma#195300ClinicalTrials.gov
• Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations.#219109NCBI PubMed Central
• Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma#234445ClinicalTrials.gov
• A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas#287555ClinicalTrials.gov
• Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.#353293ClinicalTrials.gov
• Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer#356464ClinicalTrials.gov
• Objective Sleep Characteristics and Neoadjuvant Immunotherapy Response in Gastric/GEJ Cancer#363594ClinicalTrials.gov
• Association of Psychological Distress in Patients With Lung Cancer#363624ClinicalTrials.gov
• alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells#383553ClinicalTrials.gov
• Engineering nanoparticle surface chemistry for antigen-presenting cell targeting improves specificity and safety of TLR3 agonist cancer immunotherapy#398110bioRxiv / medRxiv
• Targeting cellular components of the tumor microenvironment in solid malignancies#424948IRIS
• Global research trends and emerging frontiers of intratumoral microbiota in cancer immunotherapy: a bibliometric and visualization analysis.#430878NCBI PubMed Central
• Targeting molecular residual disease and immune escape in colorectal cancer recurrence: biomarker-guided immunotherapy and cell therapies.#433874NCBI PubMed Central
• Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma#451461ClinicalTrials.gov
• Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities#459154Springer Nature OA
• Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma#474760ClinicalTrials.gov
• Nanoparticle Platforms in Cancer Immunotherapy: A Critical Comparative Review of PLGA, Mesoporous Silica, Magnetic Nanoparticles, and Covalent Organic Frameworks.#610277NCBI PubMed Central
• FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC#651241ClinicalTrials.gov
• A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies#287543ClinicalTrials.gov
• Evaluation of the Efficacy and Safety of Adebrelimab Combined With SOX as Adjuvant Therapy for IIIB and IIIC Gastric Cancer#867559ClinicalTrials.gov
• Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases#840199ClinicalTrials.gov
• Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer#162477ClinicalTrials.gov
• Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy#208432ClinicalTrials.gov
• Supplementary file 1_Adverse events associated with targeted therapy and immunotherapy for ovarian cancer: a FAERS pharmacovigilance study.docx#300638Figshare
• Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma#800894ClinicalTrials.gov
• QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer#833520ClinicalTrials.gov
• QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy#846858ClinicalTrials.gov
• Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy#860219ClinicalTrials.gov
• Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid Tumors#861912ClinicalTrials.gov
• Impact of Respiratory Rehabilitation on Quality of Life in Patients With Metastatic Non-small Cell Lung Cancer Treated With Immunotherapy and Chemotherapy in the Maintenance Phase#866030ClinicalTrials.gov
• Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)#852205ClinicalTrials.gov
• Breast Immunology Network: Toward a Multidisciplinary and Integrated Model for Breast Cancer Care in Italy#239269IRIS
• A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor#451521ClinicalTrials.gov
• Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer#67904ClinicalTrials.gov
• Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma#127565ClinicalTrials.gov
• Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC#162460ClinicalTrials.gov
• Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer#208465ClinicalTrials.gov
• Tertiary lymphoid structures in the era of cancer therapy#257725HAL (France)
• Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy#363612ClinicalTrials.gov
• Comprehensive bioinformatics analysis identifies DNA methylation signatures associated with immune evasion and predicts immunotherapy response in breast cancer.#368180NCBI PubMed Central
• Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies#442106ClinicalTrials.gov
• Role of ctDNA Tumor Fraction in Selecting Immunotherapy-Based Regimens in Advanced Non–Small Cell Lung Cancer#468385HAL (France)
• Antigen presentation requirements for effective cDC1-based cancer immunotherapy#484988Europe PMC
• The TRIM-cancer paradox: BCG as a programmable vaccine platform and a mechanistic probe for rational immunotherapy design.#636418NCBI PubMed Central
• Impact of Gonadotoxic Therapies on Fertility#674897ClinicalTrials.gov
• Global research trends in fecal microbiota transplantation combined with immune checkpoint inhibitors for cancer immunotherapy: a bibliometric analysis.#685707NCBI PubMed Central
• In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma#866210ClinicalTrials.gov
• A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer#426769ClinicalTrials.gov